AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Tudor domain-containing protein 7 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Tudor domain-containing protein 7 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Tudor domain-containing protein 7, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Tudor domain-containing protein 7. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Tudor domain-containing protein 7. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Tudor domain-containing protein 7 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Tudor domain-containing protein 7
partner:
Reaxense
upacc:
Q8NHU6
UPID:
TDRD7_HUMAN
Alternative names:
PCTAIRE2-binding protein; Tudor repeat associator with PCTAIRE-2
Alternative UPACC:
Q8NHU6; A6NCI6; B2RBX3; B4DG99; B4DXF7; E7EQD4; Q5VV27; Q96JT1; Q9UFF0; Q9Y2M3
Background:
Tudor domain-containing protein 7, also known as PCTAIRE2-binding protein or Tudor repeat associator with PCTAIRE-2, plays a crucial role in post-transcriptional regulation of gene expression. It is involved in the formation of specific cytoplasmic RNA granules, binding to mRNAs to regulate their translation. This protein is essential for maintaining lens transparency during development by controlling the translation of key genes such as CRYBB3 and HSPB1.
Therapeutic significance:
Tudor domain-containing protein 7 is implicated in Cataract 36, a condition characterized by lens opacification leading to visual impairment or blindness. Understanding the role of Tudor domain-containing protein 7 could open doors to potential therapeutic strategies for treating or managing this eye condition.
